Why the Renaming Matters for Millions of Women
For decades, women diagnosed with Polycystic Ovary Syndrome (PCOS) have often felt that the name did not accurately reflect their experience.
Many women with PCOS do not have ovarian cysts. Others struggle more with weight gain, insulin resistance, fatigue, anxiety, fertility difficulties, acne, excess hair growth, or irregular periods than with any ovarian symptoms at all.
In May 2026, following a global consensus process involving thousands of patients, clinicians and researchers, the condition was officially renamed:
Polyendocrine Metabolic Ovarian Syndrome (PMOS).
This is far more than a simple rebranding exercise. It represents a major shift in how medicine understands and manages this common condition.
Why Was PCOS Renamed?
The term “Polycystic Ovary Syndrome” has been criticised for years because it is misleading.
Firstly, the “cysts” seen on ultrasound are not actually ovarian cysts. They are small immature follicles.
Secondly, many women diagnosed with PCOS do not have polycystic ovaries on ultrasound.
Most importantly, the name focuses attention on the ovaries when the condition affects many systems throughout the body. Researchers have argued that the old name contributed to delayed diagnosis, fragmented care and a misunderstanding of the condition’s true impact.
The new name acknowledges that this is:
- An endocrine (hormonal) condition
- A metabolic condition
- A reproductive condition
all at the same time.
What Does PMOS Mean?
Polyendocrine
This reflects the involvement of multiple hormonal systems.
Women with PMOS may have abnormalities involving:
- Ovarian hormones
- Androgens (testosterone and related hormones)
- Insulin
- Adrenal hormones
- Brain-pituitary signalling pathways
PMOS is not simply an ovarian disorder; it is a whole-body hormonal condition.
Metabolic
This is perhaps the most important addition.
Insulin resistance is a key feature for many women with PMOS and contributes to:
- Weight gain
- Difficulty losing weight
- Increased appetite and cravings
- Prediabetes
- Type 2 diabetes
- Cardiovascular disease risk
The word “metabolic” highlights something clinicians have known for years: PMOS is not only about fertility or periods. It is also about long-term health.
Ovarian
The ovaries remain important because many women experience:
- Irregular ovulation
- Irregular periods
- Difficulty conceiving
- Polycystic ovarian morphology on ultrasound
The ovarian component remains part of the condition, but it is no longer the sole focus.
Does the Diagnosis Change?
No.
The diagnostic criteria remain exactly the same for now.
Most clinicians continue to use the Rotterdam criteria, which require two of the following three features:
- Irregular or absent ovulation
- Clinical or biochemical signs of excess androgens
- Polycystic ovarian appearance on ultrasound
after excluding other medical causes.
If you previously had a diagnosis of PCOS, your diagnosis is now considered PMOS.
What Does This Mean for Patients?
1. Better Understanding
Many women have spent years being told:
“Your scan shows cysts on your ovaries.”
The new terminology helps explain that PMOS is much more complex than a scan finding.
2. More Comprehensive Care
Historically, management often focused on one symptom:
- Fertility
- Acne
- Weight
- Irregular periods
The new approach encourages clinicians to assess the whole picture:
- Metabolic health
- Cardiovascular risk
- Mental wellbeing
- Reproductive health
- Long-term disease prevention
3. Earlier Screening
Women with PMOS may have an increased risk of:
- Insulin resistance
- Type 2 diabetes
- High cholesterol
- Hypertension
- Sleep apnoea
- Anxiety and depression
The new name encourages earlier identification and monitoring of these risks.
4. Reduced Stigma
Many patients report feeling frustrated by the term “polycystic ovaries” because it does not reflect their symptoms.
The PMOS terminology better validates the experiences of women whose main challenges may be metabolic, psychological or hormonal rather than ovarian.
What About Treatment?
The name has changed, but many treatments remain the same.
Depending on symptoms and goals, management may include:
Lifestyle Medicine
- Nutrition support
- Exercise
- Sleep optimisation
- Stress management
Hormonal Treatments
- Combined contraceptive pill
- Hormonal coils
- Anti-androgen medications
Fertility Support
- Ovulation induction
- Fertility treatment where appropriate
Metabolic Treatments
- Metformin
- Inositol supplementation
- Weight management programmes
- GLP-1 medications such as Mounjaro® or Wegovy® when clinically appropriate
The difference is that these treatments are increasingly viewed as part of one integrated management strategy rather than separate approaches.
The Future of PMOS Care
The renaming to PMOS reflects a growing recognition that women’s health conditions deserve accurate terminology and comprehensive care.
For too long, this condition has been misunderstood, underdiagnosed and underfunded despite affecting approximately one in eight women worldwide. The new name helps shift the conversation from ovarian “cysts” to the broader hormonal and metabolic health issues that truly define the condition.
At 2Me Clinic, we welcome this change because it aligns with how we already care for women: looking beyond symptoms and treating the whole person.
Whether your main concern is irregular periods, fertility, acne, weight management, insulin resistance, menopause transition or long-term metabolic health, PMOS reminds us that all these factors are connected.
Key Takeaway
PMOS is the new name for PCOS.
The diagnosis has not changed, but our understanding has evolved.
The new terminology recognises that this is not simply an ovarian condition. It is a complex hormonal and metabolic syndrome that deserves a holistic, personalised approach to care.
If you have been diagnosed with PCOS—or suspect you may have PMOS—speak with a healthcare professional who understands both the reproductive and metabolic aspects of the condition.
© 2Me Clinic May 2026
